News und Analysen

Shares of Humana (NYSE: HUM) fell as much as 12.8% on Thursday after the health insurance company cut its 2023 guidance, citing rising Medicare Advantage costs amid "higher than anticipated

While the market bounced back last year, some stocks failed to keep pace with broader equities. That was the case with pharma giant AbbVie (NYSE: ABBV) and e-commerce specialist Etsy (NASDAQ: ETSY)

It's hard for me to pick my top favorite in many categories. Whether talking about actors, athletes, songs, singers, movies, or TV shows, I find it difficult to single one out as the best.

This

Shares of Alibaba Group (NYSE: BABA) were sliding again today as further signs of weakness emerged in the Chinese economy.

In an effort to restore optimism about China's recovery, the country

In this video, I will go over four healthcare stocks that represent different exposures to the healthcare industry. One of the companies I cover happens to be the fifth-largest player in the

Abbott Laboratories (NYSE: ABT) and AbbVie (NYSE: ABBV) share a common past. About a decade ago, Abbott spun out its pharmaceuticals business into a separate company to create AbbVie. Since then

One of the most important companies during the peak of the COVID-19 pandemic was pharmaceutical giant Pfizer (NYSE: PFE). The company's breakthrough vaccine helped pave the way for a post-pandemic

For all of its many successes, the healthcare industry isn't exactly a hotbed of dividend-paying stocks. However, this doesn't mean the sector is entirely without companies that remunerate their

It's been a few years since the average investor behaved as if no challenge was too tough for America's biopharmaceutical industry. In turn, shares of gene-editing startup Editas Medicine (NASDAQ:

If you're in the process of rebalancing your portfolio, you might be considering buying Pfizer (NYSE: PFE) stock. After all, the drugmaker pays a sizzling 5.92% dividend yield, its shares trade at

Last year, pharmaceutical giant Pfizer (NYSE: PFE) encountered several issues, none more significant than the massive drop in revenue and earnings it experienced due to a shrinking coronavirus

There's no guarantee that any stock is completely unstoppable. However, three Motley Fool contributors think they've identified some that come close. Here's why they picked Eli Lilly (NYSE: LLY)

Last year wasn't a particularly good one for Pfizer (NYSE: PFE). Even CEO Albert Bourla says so. "We missed our internal projections and also, we missed the expectations of The Street... And

Clinical-stage biotech Vera Therapeutics (NASDAQ: VERA) had a week to remember on the stock market. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the

While investors love when one of their companies beats analyst estimates, it's not always the case that its stock rises in reaction. That was the case Friday with big health insurance company

Image source: The Motley Fool.

UnitedHealth Group (NYSE: UNH)Q4 2023 Earnings CallJan 12, 2024, 8:45 a.m. ET

Operator

Continue reading

Source Fool.com

After a tough 2022 and gains in 2023, it's fair to say the stock market is probably on the way to better days. In any case, history tells us that bear markets, such as the one that began in 2022

There are many ways one could end up with $1 million or more by retirement. Putting enough money in a savings account or winning the lottery are among them. However, neither of these methods can

Growth stocks were back in style in 2023 after a disappointing year in 2022. However, not every growth-oriented company kept pace with the broader indexes. Here are two that didn't: Sarepta

Shares of gene sequencing leader Illumina (NASDAQ: ILMN) rallied 36.6% in December, according to data from S&P Global Market Intelligence.

Investors might not be quite so excited, as Illumina

Pharmaceutical giant Pfizer (NYSE: PFE) went through a growth spurt during the COVID-19 pandemic as one of the leading vaccine companies. But the windfall of billions of extra dollars in revenue and

Pfizer (NYSE: PFE) had a disastrous 2023, with its share price collapsing by 44%. It was one of the S&P 500's worst-performing stocks last year. The company's COVID-19 revenue nosedived as the

Investing in cutting-edge companies is a bit riskier than investing in tried-and-tested players, but breaking new ground can sometimes offer outsized rewards. On that note, Editas Medicine (NASDAQ:

Pharmaceutical company AbbVie (NYSE: ABBV) has been a double-deal of price growth and dividend income over the past five years. It achieved 129% in total returns in that time, outpacing the S&P 500.

Biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered market-beating returns over the past 12 months, five years, and 10 years. Existing shareholders are happy, but those still on the